Lord Abbett & CO. LLC Acquires 5,959 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Lord Abbett & CO. LLC lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 108,715 shares of the medical research company's stock after acquiring an additional 5,959 shares during the quarter. Lord Abbett & CO. LLC owned approximately 0.21% of Charles River Laboratories International worth $21,413,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Tortoise Investment Management LLC lifted its stake in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the 3rd quarter valued at about $32,000. Assetmark Inc. lifted its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after purchasing an additional 173 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock worth $58,000 after purchasing an additional 193 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

CRL stock traded down $0.40 during trading on Monday, hitting $190.06. The company had a trading volume of 727,953 shares, compared to its average volume of 617,117. The company has a fifty day moving average price of $194.37 and a two-hundred day moving average price of $202.82. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00. The company has a market cap of $9.72 billion, a P/E ratio of 23.79, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 EPS. The firm's quarterly revenue was down 1.6% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on CRL. Bank of America dropped their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday. StockNews.com lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective on the stock. Finally, Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $214.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).